Clene (CLNN) Current Deferred Revenue (2020 - 2021)

Clene (CLNN) posted Current Deferred Revenue of $112000.0 for Q3 2021, little changed on a QoQ basis from $112000.0 in Q2 2021.

Analysis

Clene (CLNN) Current Deferred Revenue (2020 - 2021) Analysis & Trends

Clene has reported Current Deferred Revenue for 2 years, with the latest figure at $112000.0 in Q3 2021.

On a quarterly basis, Current Deferred Revenue changed N/A year-over-year to $112000.0 in Q3 2021; TTM through Sep 2021 was $112000.0, a N/A change from a year earlier, with the FY2020 full-year figure at $112000.0, changed N/A from the prior year.
Current Deferred Revenue was $112000.0 for Q3 2021 at Clene, roughly flat from $112000.0 in the prior quarter.
The five-year high for Current Deferred Revenue was $112000.0 in Q4 2020, with the low at $112000.0 in Q4 2020.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	641.14 Bn	620.38 Bn	17.26 Bn
2	AbbVie	451.04 Bn	444.47 Bn	12.70 Bn
3	Merck	357.43 Bn	350.29 Bn	12.21 Bn
4	Novartis Ag	266.73 Bn	259.04 Bn	11.24 Bn
5	Pfizer	157.52 Bn	145.82 Bn	10.94 Bn
6	Sanofi	52.14 Bn	44.76 Bn	10.79 Bn
7	Revolution Medicines	42.88 Bn	42.88 Bn	-
8	Incyte	24.70 Bn	20.16 Bn	1.57 Bn
9	United Therapeutics	21.47 Bn	18.80 Bn	683.80 Mn
10	Clene	45.69 Mn	45.69 Mn	54,000.00

Historic Data

Download Data